EnglishFrançais

Ce site a été mis à jour le 14 mars 2017

Breast Cancer - No. 697 Imprimer
Gulisa Turashvili et al (Modern Pathology (2011) 24, 64-81; doi:10.1038/modpathol.2010.189; published online 17 September 2010) http://www.nature.com/modpathol/journal/v24/n1/full/modpathol2010189a.html reported an analysis of P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. P-cadherin expression was evaluated using immunohistochemistry. Median follow-up was 12.5 years. P-cadherin was expressed in 34.8% of cases. P-cadherin staining was strongly associated with HER2+ and basal carcinoma subtypes (P<0.0005). P-cadherin-positive patients showed significantly poorer short-term (0-10 years) overall survival, disease-specific survival, distant relapse-free interval, and locoregional relapse-free interval in univariable models (P<0.05). In multivariable Cox models containing standard clinical covariates and cancer subtypes, P-cadherin did not show independent prognostic value. P-cadherin expression was positively associated with histological grade, chemotherapy, Ki-67, EGFR, CK5/6, p53, YB-1, and HER2 expression (P<0.002), and negatively associated with age at diagnosis, ER, PR, and Bcl-2 expression (P<0.0005). This study shows the value of P-cadherin as a marker of poor prognosis. The large sample size of this series clarifies contradictory findings of many smaller studies. P-cadherin positivity is associated with high-grade tumor subtypes and well-established markers of poor prognosis, and may represent a promising antibody therapeutic target.
 
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн